Share on StockTwits

Theravance (NASDAQ:THRX)‘s stock had its “buy” rating restated by equities research analysts at Stifel Nicolaus in a research note issued to investors on Wednesday, American Banking and Market News reports. They currently have a $47.00 price target on the stock, down from their previous price target of $52.00. Stifel Nicolaus’ target price indicates a potential upside of 73.24% from the stock’s previous close.

THRX has been the subject of a number of other recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Theravance in a research note on Wednesday. They now have a $29.00 price target on the stock. Finally, analysts at Ned Davis Research upgraded shares of Theravance from a “sell” rating to a “neutral” rating in a research note on Monday, April 21st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $32.92.

Shares of Theravance (NASDAQ:THRX) traded down 0.22% during mid-day trading on Wednesday, hitting $27.13. The stock had a trading volume of 2,740,137 shares. Theravance has a 52 week low of $26.04 and a 52 week high of $42.96. The stock’s 50-day moving average is $28.91 and its 200-day moving average is $34.62. The company’s market cap is $3.038 billion.

Theravance (NASDAQ:THRX) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $0.09. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $4.52 million. During the same quarter in the previous year, the company posted ($0.39) earnings per share. The company’s revenue for the quarter was down 87.3% on a year-over-year basis. Analysts expect that Theravance will post $-1.29 EPS for the current fiscal year.

Theravance, Inc (NASDAQ:THRX) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.